Virus Destroying Or Inhibiting Patents (Class 514/3.7)
-
Patent number: 8785377Abstract: The present invention relates to compounds of Formula I, II, III or IV, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.Type: GrantFiled: January 18, 2008Date of Patent: July 22, 2014Assignee: Enanta Pharmaceuticals, Inc.Inventors: Ying Sun, Dong Liu, Yat Sun Or, Zhe Wang
-
Publication number: 20140199291Abstract: The invention relates to compositions, methods, and kits for treating subjects infected by or at risk of infection with a DNA virus (e.g., a JC Virus or a BK virus). Aspects of the invention are useful to prevent or treat DNA virus associated conditions (e.g., PML) in subjects that are immunocompromised. Compositions are provided that inhibit intracellular replication of DNA viruses.Type: ApplicationFiled: September 13, 2008Publication date: July 17, 2014Applicant: Biogen Idec MA IncInventors: Leonid Gorelik, Margot Brickelmaier, Alexey Lugovskoy
-
Patent number: 8778875Abstract: An active biological substance is disclosed for use in abnormal cellular and viral membrane physiologies in human and mammal organisms. The active substance has diagnostic and/or therapeutic properties and contains or consists of at least one component selected from the group of substances including: histones, covalently modified histones, histone-like polypeptides, biologically active histone sequences and histone-like polypeptides as agents for stopping the supply to solid tumors over their blood vessels, for killing cells infected by virus and for killing tumour cells with disturbed lipid asymmetry.Type: GrantFiled: August 4, 2006Date of Patent: July 15, 2014Assignee: Symbiotec Gesellschaft zur Forshung und Entwickling auf dem Gebiet der Biotechnologie, mbHInventors: Michael Zeppezauer, Peter Gross
-
Patent number: 8778876Abstract: The present invention concerns methods and compositions involving small molecule inhibitors for the treatment or prophylaxis of flavivirus infection, such as dengue virus and West Nile virus.Type: GrantFiled: March 5, 2012Date of Patent: July 15, 2014Assignee: The Board of Regents of the University of Texas SystemInventors: Stanley J. Watowich, Suzanne M. Tomlinson, Scott Gilbertson
-
Publication number: 20140194348Abstract: Methods for inhibiting virus proliferation and treating an individual having a papillomavirus infection preventing viral infection are disclosed. The methods include the steps of providing a composition comprising a plurality of papillomavirus virus-like particles or capsomeres and contacting papillomavirus-infected tissue of an individual with the composition under conditions effective to inhibit papillomavirus proliferation or treat the papillomavirus infection in the individual.Type: ApplicationFiled: January 7, 2014Publication date: July 10, 2014Applicant: UNIVERSITY OF ROCHESTERInventor: William Bonnez
-
Publication number: 20140194350Abstract: The present invention discloses compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: January 2, 2014Publication date: July 10, 2014Applicant: Enanta Pharmaceuticals, Inc.Inventors: Yat Sun Or, Jun Ma, Guoqiang Wang, Jiang Long, Bin Wang
-
Publication number: 20140194347Abstract: The present invention provides peptides, peptide analogs, peptide derivatives and pharmaceutical compositions useful for treating or preventing influenza infections or preventing the person-to-person transmission of an influenza infection. A peptide of the invention comprises an influenza virus-cell fusion inhibiting portion of the fusion initiation region (FIR) of a wild-type influenza hemagglutinin 2 protein or a variant thereof. In a preferred embodiment, a peptide of the invention consists of 8 to 40 consecutive amino acid residues a portion of a wild-type influenza hemagglutinin 2 protein or a variant thereof, the portion of the protein comprising the FIR of the protein and up to five amino acid residues on the amino-terminal and carboxy-terminal sides of the FIR.Type: ApplicationFiled: December 10, 2013Publication date: July 10, 2014Applicants: Autoimmune Technologies, LLC, The Administrators of the Tulane Educational FundInventors: Robert F. GARRY, Russell B. WILSON
-
Publication number: 20140194345Abstract: The present invention relates generally to novel depsipeptides, to methods for the preparation of these novel depsipeptides, to pharmaceutical compositions comprising the novel depsipeptides; and to methods of using the novel depsipeptides to treat or inhibit various disorders.Type: ApplicationFiled: December 3, 2013Publication date: July 10, 2014Inventors: Aaron J. Peoples, Dallas Hughes, Losee Lucy Ling, William Millett, Anthony Nitti, Amy Spoering, Victoria Alexandra Steadman, Jean-Yves Christophe Chiva, Linos Lazarides, Michael Kenyon Jones, Karine Gaelle Poullenec, Kim Lewis
-
Publication number: 20140187474Abstract: A therapeutic formulation containing mucin glycans derived from one or a number of nutritionally appropriate sources is described.Type: ApplicationFiled: March 6, 2014Publication date: July 3, 2014Inventor: Justin L. Sonnenburg
-
Patent number: 8759281Abstract: The present invention relates to fluorocarbon vectors for the delivery of antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals.Type: GrantFiled: January 20, 2012Date of Patent: June 24, 2014Assignee: Immune Targeting Systems Ltd.Inventors: Dominique Bonnet, Carlton B. Brown, Bertrand Georges, Philip J. Sizer
-
Patent number: 8754042Abstract: The present invention relates to novel agents, pharmaceutical compositions containing them, and their use in therapy, particularly anti-microbial and anti-cancer therapy. In particular, the present invention relates to novel peptide-based compounds based on SEQ ID NO:40 which have surprisingly been shown to have inhibitory effects on the growth and/or viability of cells, particularly bacterial and cancer cells. Also provided are therapeutic and non-therapeutic methods which comprise the use of peptides of the invention.Type: GrantFiled: February 1, 2011Date of Patent: June 17, 2014Assignee: Cytovation ASInventor: Lars Prestegarden
-
Patent number: 8748373Abstract: A polypeptide comprising a preS1 region of hepatitis B virus (HBV), or a fragment thereof, and/or the preS2 region of HBV or a fragment thereof, and methods of use to inhibit virus infection are disclosed. A lentivirus comprising hepatitis B virus (HBV) envelope proteins, or a fragment thereof, and/or the L envelope protein of HBV and/or the M envelope protein of HBV or a fragment thereof, and/or the S envelope protein of HBV or a fragment thereof, and methods of use of this lentivirus HBV pseudovirus as a gene therapy to target hepatocytes for the administration of therapeutic agents are also disclosed.Type: GrantFiled: February 20, 2008Date of Patent: June 10, 2014Assignee: Fox Chase Cancer CenterInventors: Ning Chai, John M. Taylor
-
Publication number: 20140154208Abstract: The present invention relates to novel cyclosporine analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporine analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.Type: ApplicationFiled: November 27, 2013Publication date: June 5, 2014Applicant: ENANTA PHARMACEUTICALS, INC.Inventors: Yat Sun Or, In Jong Kim, Jiang Long, Lijuan Jiang, Sheng Sean Liu, Guoqiang Wang
-
Publication number: 20140142033Abstract: Analogues of cyclosporin-A are disclosed comprising modifications of the substituents as the positions of amino acids 1 and 3, according to the following Formula. The disclosed compounds include compounds having affinity for cyclophilin, including cyclophilin-A, and reduced immunosuppressivity in comparison with cyclosporin-A and analogs thereof modified solely at position 1.Type: ApplicationFiled: December 14, 2011Publication date: May 22, 2014Applicant: Isotechnika Pharma Inc.Inventors: Alexander Hegmans, Bruce W. Fenske, Dan J. Trepanier, Mark D. Abel, Daren R. Ure, Shin Sugiyama
-
Publication number: 20140134132Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein the variables R1, R2, R3, R4, R5, and A-B are defined herein, which are non-immunosuppresive, cyclophilin-binding, mPTP blockers and are therefore useful for the prevention or treatment of diseases or disorders such as HCV infection, stroke, multiple sclerosis, HBV infection, HPV infection, asthma, cancer, muscular dystrophy, sepsis, ischemia/reperfusion injury, and heart failure.Type: ApplicationFiled: September 26, 2013Publication date: May 15, 2014Applicant: NOVARTIS AGInventors: Jiping Fu, Subramanian Karur, Xiaolin Li, Peichao Lu, Wosenu Mergo, Alexey Rivkin, Zachary Kevin Sweeney, Meiliana Tjandra, Andrew Weiss, Aregahegn Yifru
-
Publication number: 20140134237Abstract: The subject invention pertains to agonist peptides of type I interferons and methods of using the peptides. These peptides are based on the amino acid sequence of the C-terminus region of the type I IFN molecules and are capable of binding to the cytoplasmic domain of type I IFN receptors. Surprisingly, these peptides were found to possess the same or similar biological activity as that associated with the full-length, mature type I IFN proteins, even though these peptides do not bind to the extracellular domain of the type I IFN receptors. In one embodiment, the peptide is a peptide of IFN?. In another embodiment, the peptide is a peptide of IFN?. Exemplified peptides of the invention include those having SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:38, SEQ ID NO:39, and SEQ ID NO:40. The subject peptides have been shown to effect increased resistance to viral infection.Type: ApplicationFiled: December 11, 2013Publication date: May 15, 2014Inventors: HOWARD M. JOHNSON, CHULBUL M. AHMED
-
Patent number: 8722853Abstract: The present invention provides compositions, compounds, and methods relating to recombinant adenoviral-based polypeptides for treating disorders associated with epithelial tissues.Type: GrantFiled: June 10, 2011Date of Patent: May 13, 2014Assignee: University of Washington through its Center for CommercializationInventors: Andre Lieber, Hongjie Wang
-
Patent number: 8722616Abstract: Anti-HIV peptides and methods of use are provided. In particular, these HIV inhibitory peptides are discovered based on the Antimicrobial Peptide Database.Type: GrantFiled: October 19, 2010Date of Patent: May 13, 2014Assignee: Board of Regents of the University of NebraskaInventor: Guangshun Wang
-
Publication number: 20140128317Abstract: The invention relates to an antiviral agent containing recombinant mistletoe lectins for treating virus infections and to a medicament and/or pharmaceutical composition for treating virus infections.Type: ApplicationFiled: February 1, 2012Publication date: May 8, 2014Applicant: Cytavis Biophama GmnHInventors: Hans Lentzen, Klaus Witthohn
-
Patent number: 8716246Abstract: Azuvirin peptides are small peptide agents useful in delivering functional moieties, such as sensitizers, chemotherapeutic agents and the like to cancer cells expressing ephrin receptors. The peptides are also useful for administration to a patient suffering from a viral infection, or to an individual facing exposure to a viral infection, especially one caused by the Human Immunodeficiency Virus (HIV-1).Type: GrantFiled: January 3, 2012Date of Patent: May 6, 2014Assignee: The Regents of the University of CaliforniaInventors: Piotr P. Ruchala, Robert I. Lehrer
-
Patent number: 8716454Abstract: The present invention features solid compositions comprising Compound IA, IB or IC, or a pharmaceutically acceptable salt thereof, in an amorphous form. In one embodiment, Compound IA, IB or IC, or a pharmaceutically acceptable salt thereof, is formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant.Type: GrantFiled: June 9, 2011Date of Patent: May 6, 2014Assignee: Abbvie Inc.Inventors: Simon Kullmann, Ulrich Westedt, Mirko Pauli, Rudolf Schroeder, Gerd Woehrle, Tanja Heitermann, Renato Koenig, Madlen Thiel, Yi Gao, Jianwei Wu, Bryan K. Erickson
-
Patent number: 8709999Abstract: Provided herein are compounds, pharmaceutical compositions and combination therapies for treatment of hepatitis C.Type: GrantFiled: March 26, 2010Date of Patent: April 29, 2014Assignee: Presidio Pharmaceuticals, Inc.Inventors: Min Zhong, Leping Li
-
Publication number: 20140113855Abstract: This disclosure features modified release pharmaceutical formulations (e.g., extended release pharmaceutical formulations; e.g., solid dosage forms, e.g., tablets) that are useful for the oral administration of oprozomib, or a pharmaceutically acceptable salt thereof, to a human or animal subject as well as methods of making and using the formulations.Type: ApplicationFiled: October 24, 2013Publication date: April 24, 2014Inventors: Mouhannad Jumaa, Tony Muchamuel, Naveen Bejugam, Hansen Wong, Christopher J. Kirk, Rahul Vishram Manek, Sanjeev Sharma
-
Patent number: 8703700Abstract: Inhibitors of the hepatitis C virus (HCV) NS3 protease are provided. In particular, bimacrocyclic compounds and their pharmaceutical compositions for the treatment of HCV infections are provided. Methods of making the bimacrocyclic compounds and their pharmaceutical compositions, and methods of using the compounds for treating HCV infections are also provided.Type: GrantFiled: May 24, 2010Date of Patent: April 22, 2014Assignee: Sequoia Pharmaceuticals, Inc.Inventors: Pavel Majer, Michael Eissenstat, Rongjuan Lu
-
Publication number: 20140107014Abstract: The present invention provides compositions, compounds, and methods relating to recombinant adenoviral-based polypeptides for treating disorders associated with epithelial tissues.Type: ApplicationFiled: October 29, 2013Publication date: April 17, 2014Applicant: University of Washington through its Center for CommercializationInventors: Andre Lieber, Hongjie Wang
-
Patent number: 8691760Abstract: Use of an isolated peptide comprising an amino acid sequence being no more than 25 amino acids in length, the amino acid sequence comprising at least one aspartate or a homolog thereof, the peptide having an Insulin-Degrading Enzyme (IDE) inhibitory activity, for the manufacture of a medicament identified for treating a disease selected from the group consisting of diabetes, obesity, hyperglycemia, retinal damage, renal failure, nerve damage, microvascular damage and varicella-zoster virus (VZV) infection is disclosed.Type: GrantFiled: February 2, 2010Date of Patent: April 8, 2014Assignee: Ramot at Tel-Aviv UniversityInventors: Dan Frenkel, Adi Kopelevich, Veronica Lifshitz, Tali Benromano, Nofit Borenstein
-
Patent number: 8691757Abstract: Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.Type: GrantFiled: June 11, 2012Date of Patent: April 8, 2014Assignee: Bristol-Myers Squibb CompanyInventors: Ramkumar Rajamani, Kishore V. Renduchintala, Kandhasamy Sarkunam, Pulicharla Nagalakshmi, Nicholas A. Meanwell, Paul Michael Scola
-
Publication number: 20140086936Abstract: The present invention provides matriptase inhibitors and compositions for treating and preventing orthomyxovirus infections such as flu infections. The present invention also provides novel compounds, compositions, methods of use, uses and kits thereof for inhibiting matriptase. Such compounds are useful for treating and preventing orthomyxovirus infections, such as flu infections, and for inhibiting tumor growth, progression and/or metastasis.Type: ApplicationFiled: May 28, 2012Publication date: March 27, 2014Applicant: SOCPRA SCIENCES SANTE ET HUMAINES S.E.C.Inventors: Martin Richter, Richard Leduc, Eloic Colombo, Eric Marsault
-
Publication number: 20140087998Abstract: The present invention relates to the use of pituitary adenylate cyclase activating polypeptide (PACAP) in the treatment of viral diseases and infectious diseases caused by viruses in aquatic organisms. PACAP, alone or combined with an antiviral molecule, demonstrated its effectiveness by increasing the survival of fish or crustaceans infected by viruses when it was administered orally, by injection or by immersion baths. Furthermore, it was observed that treated organisms keep or increase its weight as compared to infected and non-treated organisms. PACAP or PACAP-containing combinations decreased the viral load in tissues and organs susceptible to viral infections as it was determined by RT-PCR.Type: ApplicationFiled: November 30, 2011Publication date: March 27, 2014Applicant: CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIAInventors: Mario Pablo Estrada Garcia, Juana Maria Lugo Gonzalez, Yamila Carpio Gonzalez, Carolina Tafalla Piñeiro
-
Patent number: 8680046Abstract: Described herein are compositions and methods for inhibiting HIV integrase activity. Also described are methods of identifying agents that inhibit HIV integrase for use in treating or preventing HIV. Also disclosed are methods of identifying agents that inhibit HIV viral mutants that are resistant to integrase inhibitors.Type: GrantFiled: March 18, 2010Date of Patent: March 25, 2014Assignees: Integratech Proteomics, LLC, The United States of America, as represented by the Secretary of the Department of Health and Human ServicesInventors: Tanya Sandrock, Robert Craigie
-
Publication number: 20140080753Abstract: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.Type: ApplicationFiled: November 12, 2013Publication date: March 20, 2014Applicant: Onyx Therapeutics, Inc.Inventors: Kevin D. SHENK, Francesco PARLATI, Han-jie ZHOU, Catherine SYLVAIN, Mark S. SMYTH, Mark K. BENNETT, Guy J. LAIDIG
-
Publication number: 20140082769Abstract: The present application belongs to the field of functional peptides and more particularly to the field of controlled protein aggregation. The invention discloses molecules of a peptide structure as defined in the claims and methods of using such molecules for therapeutic applications and for diagnostic uses, as well as in other applications such as in the agbio field and in industrial biotechnology. The molecules can be used for curing and/or stabilizing infections such as bacterial, fungal and viral diseases, but are also useful in non-infectious human and veterinary diseases. The molecules can also be used for the detection of protein biomarkers and for the prognosis and diagnosis of a variety of diseases.Type: ApplicationFiled: March 12, 2012Publication date: March 20, 2014Inventors: Joost Schymkowitz, Frederic Rousseau
-
Patent number: 8674063Abstract: The present invention is relative to chimerical peptides, whose primary structure holds at least one segment which inhibits the activation of the NS3 protease of a virus from the Flaviviridae family, they also contain a cell penetrating segment and they are capable of inhibiting or attenuate the viral infection. This invention is also relative to pharmaceutical compounds which contain these chimerical peptides for the prevention and/or treatment of the infection caused by a virus of the Flaviviridae family.Type: GrantFiled: October 30, 2007Date of Patent: March 18, 2014Assignee: Centro de Ingenieria Genetica y BiotecnologiaInventors: Glay Chinea Santiago, Vivian Huerta Galindo, Alejandro Miguel Martin Dunn, Noralvis Fleitas Salazar, Osmany Guirola Cruz, Patricia Gabriela Toledo Mayora, Mónica Sarría Núñez, Alexis Musacchio Lasa, Olvaldo Reyes Acosta, Hilda Elisa Garay Pérez, Anìa Cabrales Rico
-
Patent number: 8673849Abstract: The present invention relates to monomeric and multimeric peptidic compounds which have antiviral activity, particularly against integrin-using viruses, more particularly against rotavirus. Further, the present invention refers to compositions comprising said peptidic compounds for medical use or for use as food additives.Type: GrantFiled: May 31, 2011Date of Patent: March 18, 2014Assignee: ROTALACTIS SrlInventors: Amedeo Conti, David Lembo, Claudio Fabris, Enrico Bertino, Santo Landolfo
-
Publication number: 20140066366Abstract: There is provided a biologically-active agent, in particular, for the early diagnosis and/or preventative therapy of virally-infected living cells, the efficacy of which is selective for the cell membranes of the virally-infected cells, which are modified after viral infection. The agent includes at least one component, selected from a group of materials, including recombinant human histone H1 or at least an H1 subtype or the active portion thereof. The appropriate biological activity for killing a virally-infected cell at the modified cell membrane thereof through cooperation with similarly or differently active agent components may be achieved, which together form a biologically-effective complex with increased biological activity.Type: ApplicationFiled: November 7, 2013Publication date: March 6, 2014Applicant: Symbiotic Genellschaft zur Erforschung auf dem Geibeit der Biotechnologie, MBHInventor: Reiner Class
-
Publication number: 20140056906Abstract: The invention provides human secreted proteins (SECP) and polynucleotides which identify and encode SECP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of SECP.Type: ApplicationFiled: October 8, 2013Publication date: February 27, 2014Applicant: INCYTE CORPORATIONInventors: Henry Yue, Monique G. Yao, Ameena R. Gandhi, Mariah R. Baughn, Anita Swarnakar, Narinder Walia, Madhusudan M. Sanjanwala, Michael Thorton, Vicki S. Elliott, Yan Lu, Kimberly J. Gietzen, Neil Burford, Li Ding, April J. A. Hafalia, Y. Tom Tang, Olga Bandman, Bridget A. Warren, Cynthia D. Honchell, Dyung Aina M. Lu, Kavitha Thangaveln, Sally Lee, Yuming Xu, Junming Yang, Preeti G. Lal, Bao Tran, Craig H. Ison, Brendan M. Duggan, Stephanie Sapperstein
-
Publication number: 20140057830Abstract: Alphabodies that specifically bind to cytokines or growth factor and/or their receptors, as well as polypeptides that comprise or essentially consist of such Alphabodies. Further nucleic acids encoding such Alphabodies; methods for preparing such Alphabodies and polypeptides; host cells expressing or capable of expressing such Alphabodies and polypeptides; compositions, and in particular pharmaceutical compositions, that comprise such Alphabodies, polypeptides, nucleic acids and/or host cells; and uses of such Alphabodies or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes.Type: ApplicationFiled: January 6, 2012Publication date: February 27, 2014Applicant: COMPLIX SAInventors: Ignace Lasters, Johan Desmet, Maria Henderikx, Anita Wehnert, Geert Meersseman
-
Publication number: 20140050793Abstract: The present invention includes a composition comprising a gold nanoparticle complexed with a cysteine-containing peptide. The invention also includes the method of preparing a composition comprising a gold nanoparticle complexed with a cysteine-containing peptide. The invention further includes a method of causing virolysis of a virus using the compositions described therein.Type: ApplicationFiled: October 5, 2011Publication date: February 20, 2014Applicant: Drexel UniversityInventors: Irwin Chaiken, Arangassery Rosemary Bastian, Kantharaju
-
Patent number: 8652514Abstract: Novel peptides having antimicrobial activity, and compositions containing the same.Type: GrantFiled: December 13, 2010Date of Patent: February 18, 2014Assignees: Centre National de la Recherche Scientifique, Universite des Sciences et Technologies de LilleInventors: Aurélle Tasiemski, Michel Salzet, Françoise Gaill
-
Patent number: 8653025Abstract: The present invention discloses the structure, preparation methods and uses of a series of novel polyheterocyclic based compounds (Ia-Ib and IIa-IIb) that are highly effective for inhibiting hepatitis C virus (HCV): where the structural variables are defined herein. The present invention is also provides a method of treating HCV infection by the polyheterocyclic based HCV inhibitory compounds, compositions and therapeutic methods.Type: GrantFiled: January 27, 2011Date of Patent: February 18, 2014Assignee: AB Pharma Ltd.Inventor: Zheng-Yun James Zhan
-
Publication number: 20140045743Abstract: The present invention provides compositions and methods for treating a coronavirus infection. A method embodiment comprises administering a polypeptide (preferably in a biocompatible pharmaceutical carrier) to a subject suffering from a coronavirus infection. The polypeptide comprises or consists of at least a portion of the fusion initiation region (FIR) of a coronavirus fusion protein. In some embodiments, the polypeptide comprises or consists of a sequence selected from SEQ ID NO: 2, 22, 23, 24, and 25 or an 8 to 40 contiguous amino acid residue portion thereof.Type: ApplicationFiled: August 8, 2013Publication date: February 13, 2014Applicants: Autoimmune Technologies, LLC, The Administrators of the Tulane Educational FundInventors: Robert F. GARRY, Russell B. WILSON, I
-
Publication number: 20140045742Abstract: The current invention comprises a fusion polypeptide comprising a serpin-finger polypeptide conjugated to a biologically active polypeptide optionally via a peptidic linker polypeptide. Another aspect is a protein complex of the serpin-finger fusion polypeptide and a serpin, wherein the fusion polypeptide is incorporated in the serpin into the middle of beta-sheet A as strand 4a. Also an aspect of the current invention is the in vitro preparation of the protein complex. The serpin-finger polypeptide targets and anchors the biologically active polypeptide with high affinity and functional spatial orientation.Type: ApplicationFiled: March 14, 2013Publication date: February 13, 2014Inventor: HOFFMANN-LA ROCHE INC.
-
Publication number: 20140044776Abstract: The invention includes a heparin activated Antithrombin III encapsulated into a sterically stabilized anti-HLA-DR immunoliposome for the treatment of a HIV infection in a human patient.Type: ApplicationFiled: October 21, 2013Publication date: February 13, 2014Inventor: Ralf Geiben-Lynn
-
Publication number: 20140037634Abstract: The present invention relates to novel regulatory T cell proteins. One protein, designated PD-L3, resembles members of the PD-L1 family, and co-stimulates ?CD3 proliferation of T cells in vitro. A second, TNF-like, protein has also been identified as being upregulated upon ?CD3/?GITR stimulation. This protein has been designated Treg-sTNF. Proteins, antibodies, activated T cells and methods for using the same are disclosed. In particular methods of using these proteins and compounds, preferably antibodies, which bind or modulate (agonize or antagonize) the activity of these proteins, as immune modulators and for the treatment of cancer, autoimmune disease, allergy, infection and inflammatory conditions, e.g.Type: ApplicationFiled: May 24, 2013Publication date: February 6, 2014Inventors: Randolph J. Noelle, Li Wang
-
Patent number: 8642531Abstract: The present invention relates to fluorocarbon vectors for the delivery of influenza antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-influenza antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals, including humans.Type: GrantFiled: August 29, 2008Date of Patent: February 4, 2014Assignee: Immune Targeting Systems Ltd.Inventors: Dominique Bonnet, Carlton B. Brown, Bertrand Georges, Philip J. Sizer
-
Publication number: 20140030218Abstract: A method of treating a patient having an autoimmune disease or a Th1 polarising infection or a condition associated with inflammation other than asthma or allergy, the method comprising administering to the patient a therapeutically effective amount of an inhibitor of Interferon Regulatory Factor 5 (IRF5).Type: ApplicationFiled: January 5, 2012Publication date: January 30, 2014Applicant: IMPERIAL INNOVATIONS LIMITEDInventors: Irina Alexandrovna Udalova, Thomas Krausgruber, Marc Feldmann, David Saliba, Hayley Eames
-
Publication number: 20140030221Abstract: Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.Type: ApplicationFiled: June 7, 2013Publication date: January 30, 2014Inventors: Caroline Aciro, Victoria Alexandra Steadman, Simon Neil Pettit, Karine G. Poullennec, Linos Lazarides, David Kenneth Dean, Neil Andrew Dunbar, Adrian John Highton, Andrew John Keats, Dustin Scott Siegel, Kapil Kumar karki, Adam James Schrier, Petr Jansa, Richard Mackman
-
Patent number: 8637456Abstract: The present invention provides novel agents for broad spectrum influenza neutralization. The present invention provides agents for inhibiting influenza infection by bind to the influenza virus and/or hemagglutinin (HA) polypeptides and/or HA receptors, and reagents and methods relating thereto. The present invention provides a system for analyzing interactions between infolds and the interaction partners that bind to them.Type: GrantFiled: January 27, 2011Date of Patent: January 28, 2014Assignee: Massachusetts Institute of TechnologyInventors: Ram Sasisekharan, Karthik Viswanathan, Venkataramanan Soundararajan, S. Raguram, Viswanathan Sasisekharan, Vidya Subramanian
-
Publication number: 20140024576Abstract: Compounds having the general formula (I) pharmaceutical compositions containing them for use in inhibiting bacterial heptose biosynthesis and thereby lowering or suppressing bacterial virulence.Type: ApplicationFiled: December 1, 2011Publication date: January 23, 2014Applicant: LABORATOIRE BIODIMInventors: Vincent Gerusz, Stéphane Vincent, Mayalen Oxoby, Dmytro Atamanyuk, François Moreau, Mounir Andaloussi, Abdellatif Tikad
-
Patent number: 8633230Abstract: The present disclosure relates to methods for treating viral hepatitis, compounds useful in the treatment of viral hepatitis, and pharmaceutical compositions comprising such compounds. In one embodiment, pharmaceutical compositions comprising nitazoxanide, tizoxanide, or derivatives and/or mixtures thereof are provided, as well as methods of treating hepatitis C using such compositions.Type: GrantFiled: January 9, 2007Date of Patent: January 21, 2014Inventor: Jean-Francois Rossignol